Conference Track

Breast Cancer

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Dietary Fat Reduction Improves Relapse-Free Survival in Postmenopausal Women Previously Treated For Early Stage Breast Cancer
Gene Assay and Quantitative ER Gene Expression Highly Predictive of Response to Tamoxifen Therapy
Adjuvant Letrozole Provides Greater Disease-Free Survival Than Tamoxifen in Postmenopausal Women With Receptor-Positive Breast Cancer
Adjuvant Doxorubicin/Docetaxel and Doxorubicin/Cyclophosphamide Provide Comparable Disease-Free Survival
Long-Term Statin Therapy Reduces Incidence of Breast Cancer
Alternating Regimen Improves Survival Compared With Doxorubicin/Cyclophosphamide as First-Line Therapy for Metastatic Breast Cancer
Circulating Cell Changes Predict Response in Advanced Breast Cancer Patients Receiving Bevacizumab and Erlotinib
Trastuzumab Toxicity Acceptable When Added to Adjuvant Pacitaxel and Doxorubicin/Cyclophosphamide for Early Breast Cancer
Receptor Tyrosine Kinase Inhibitor SU11248 Safe and Active in Heavily Pretreated Patients With Metastatic Breast Cancer
New Taxane Derivative Shows Activity in Metastatic Breast Cancer Patients Previously Treated With Taxanes
Autologous Transplant With High-Dose Chemotherapy Not Warranted for Patients With Primary Breast Cancer and ≥ 4 Positive Nodes
Gemcitabine and Capecitabine Combinations Have Similar Efficacy But Different Safety Profiles in Metastatic Breast Cancer
Addition of Prophylactic Growth Factors to Docetaxel-based Chemotherapy Improves Toxicity and Quality of Life in Patients With Node-Negative Breast Cancer
HER-2 Overexpression, PR Negativity, and High Ki-67 Expression Predict Poor Response in Node-Positive Breast Cancer Patients
Dose-Dense Chemotherapy Feasible in Early Breast Cancer
Bevacizumab Added to Paclitaxel Significantly Prolongs Progression-free Survival and Improves Response Rate in Patients With Locally Recurrent or Metastatic Breast Cancer
Adjuvant Paclitaxel/Trastuzumab After Doxorubicin/Cyclophosphamide Significantly Prolongs Disease-Free Survival Among HER2-Positive Breast Cancer Patients
Concurrent Paclitaxel/Trastuzumab More Effective Than Sequential Paclitaxel/Trastuzumab Following Doxorubicin/Cyclophosphamide in Resected HER-2-Positive Breast Cancer
Trastuzumab Following Adjuvant Chemotherapy Prolongs Disease-Free Survival in Patients With HER2-Positive Breast Cancer

Expert Analysis

Breast Cancer

Program Director:
Roy A. Beveridge, MD

Faculty:
Howard A. Burris III, MD Clifford A. Hudis, MD Joyce O’Shaughnessy, MD
George W. Sledge, Jr., MD Christy Russell, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent data regarding efficacy and cardiovascular risk of trastuzumab therapy in the adjuvant treatment of breast cancer
List recently investigated breast cancer treatment approaches incorporating high-dose or dose-dense chemotherapy
Recount data regarding the role of dietary intervention and lipid-lowering drugs on the risk of breast cancer

Earn CME credit by reading the expert analysis and commentary on breast cancer. Topics covered include:

WINS: Dietary Fat Reduction and Breast Cancer Recurrence
Effect of Statin Use on Breast Cancer Risk
NSABP B-14: Prognostic Factors
Circulating Endothelial Cells Predict Stable Disease in Metastatic Breast Cancer
Prognostic and Predictive Biomarkers
Adjuvant Letrozole vs Tamoxifen in Postmenopausal Women
Adjuvant AT vs AC
SWOG 9623: High-dose Chemotherapy in Node-Positive Breast Cancer
Pilot Study of Increased Dose-Density Chemotherapy
New Agents in Previously Treated Metastatic Breast Cancer: SU11248 and Lapatinib
NCCTG 9831: Adjuvant Trastuzumab and Cardiovascular Risk
E2100: Bevacizumab As First-Line Therapy in Metastatic Breast Cancer
Joint Analysis of NCCTG 9831 and NSABP B-31
HERA Trial

CME CREDIT INFORMATION

Release Date: 07/18/05

Expiration Date: 07/17/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.